Advertisement

Cancer Immunology, Immunotherapy

, Volume 9, Issue 1–2, pp 69–72 | Cite as

Treatment of carcinoma in situ of the bladder with BCG

A phase II trial
  • Alvaro Morales
Original Articles

Summary

Although carcinoma in situ conveys the idea of an early neoplasm, such lesions in the bladder mucosa commonly exhibit a very aggressive behavior and carry a grave prognosis. Seven patients with in situ carcinoma of the bladder have been treated with intravesical and systemic administration of Bacillus Calmette-Guérin. Elimination of tumor was documented by endoscopy, histology and cytology in five patients. These five patients have remained tumor-free for periods ranging between 12 and 33 months (mean: 22.6). This preliminary study indicates that regional and systemic immunotherapy is an alternative worth additional investigation in patients with carcinoma in situ of the bladder.

Keywords

Carcinoma Cancer Research Aggressive Behavior Systemic Administration Additional Investigation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Althausen AF, Prout GR, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116:575Google Scholar
  2. 2.
    Daly JJ (1976) Carcinoma in situ of the urothelium. Urol Clin North Am 3:87Google Scholar
  3. 3.
    Douville Y, Roy R, Charrois R, Kibrite A, Martin M, Dionne L, Coulonval L, Robinson J (1978) Recurrent bladder papillomata treated with BCG. A preliminary report. Cancer Treat Rep 62:661Google Scholar
  4. 4.
    Eisenberg RB, Roth RB, Schweinsberg MH (1960) Bladder tumors and associated proliferative mucosal lesions. J Urol 84:544Google Scholar
  5. 5.
    Farrow GM, Utz DC, Rife CC (1977) Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 37:2794Google Scholar
  6. 6.
    Melamed MR, Voutsa NG, Grabstald H (1964) Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. Cancer 17:1533Google Scholar
  7. 7.
    Melicow MM (1952) Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 68:261Google Scholar
  8. 8.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180PubMedGoogle Scholar
  9. 9.
    Schade ROK, Swinney J (1973) The association urothelial atypism with neoplasia: its importance in treatment and prognosis. J Urol 109:619Google Scholar
  10. 10.
    Skinner DG, Richie JP, Cooper PH (1974) The clinical significance of carcinoma in situ of the bladder and it's association with overt carcinoma. J Urol 112:68Google Scholar
  11. 11.
    Utz DC, Hanash KD, Farrow GM (1970) The plight of the patient with carcinoma in situ of the bladder. J Urol 102:160Google Scholar
  12. 12.
    Whitmore WF, Jr, Phillips RF, Grabstald H (1963) Experience with pre-operative irradiation followed by radical cystectomy for treatment of bladder cancer. Am J Roentgenol 90:1016Google Scholar
  13. 13.
    Zbar B, Ribi E, Rapp HJ (1973) An experimental model for immunotherapy of cancer. Natl Cancer Inst Monogr 39:3Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • Alvaro Morales
    • 1
  1. 1.Department of UrologyQueen's UniversityKingstonCanada

Personalised recommendations